Literature DB >> 2533894

Pharmacological and anti-emetic properties of ondansetron.

M B Tyers1, K T Bunce, P P Humphrey.   

Abstract

Three main types of 5-HT (serotonin) receptor have been recognised. The 5-HT3 receptor is located on neuronal tissues in the peripheral and central nervous systems. Ondansetron is a highly selective and potent antagonist for this receptor type. The severe nausea and vomiting caused by cytotoxic agents and radiotherapy can be reduced by metoclopramide treatment, but extrapyramidal side effects are common due to antagonism of dopamine receptors. Ondansetron has been found to significantly delay the onset of emesis, and reduce the number of retches and vomits in ferrets receiving cisplatin, cyclophosphamide, or radiation, at much lower doses than metoclopramide and without the associated side effects. Experiments to define the site of action of ondansetron suggest that at least part of its antiemetic action is in the area postrema, though a peripheral site of action in the upper gastrointestinal tract is also a possibility.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2533894

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  19 in total

1.  Mechanism of the prostanoid TP receptor agonist U46619 for inducing emesis in the ferret.

Authors:  Kelvin K W Kan; Man P Ngan; Man K Wai; John A Rudd
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-11       Impact factor: 3.000

Review 2.  5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis.

Authors:  M S Aapro
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

3.  Effect of ondansetron on post-dural puncture headache (PDPH) in parturients undergoing cesarean section: a double-blind randomized placebo-controlled study.

Authors:  Zainabosadat Fattahi; Seyed Mohammad Reza Hadavi; Mohammad Ali Sahmeddini
Journal:  J Anesth       Date:  2015-03-27       Impact factor: 2.078

Review 4.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

5.  Sir David Jack: an extraordinary drug discoverer and developer.

Authors:  Clive Page; Patrick Humphrey
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

6.  A comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after tympanoplasty.

Authors:  A A van den Berg
Journal:  Can J Anaesth       Date:  1996-09       Impact factor: 5.063

7.  The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.

Authors:  E I Ashforth; J L Palmer; A Bye; A Bedding
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

Review 8.  Antiemetics in cancer chemotherapy: historical perspective and current state of the art.

Authors:  M Tonato; F Roila; A Del Favero; E Ballatori
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

9.  The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment.

Authors:  J C Blake; J L Palmer; N A Minton; A K Burroughs
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

10.  Biotransformation of the antiemetic 5-HT3 antagonist tropisetron in liver and kidney slices of human, rat and dog with a comparison to in vivo.

Authors:  A E Vickers; V Fischer; M S Connors; W A Biggi; F Heitz; J P Baldeck; K Brendel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.